-
FDA Approves Lamlique (lamotrigine) Oral Suspension for Seizures and Bipolar Disorder
September 29, 2026 — Azurity Pharmaceuticals, a privately held global pharmaceutical company dedicated to redefining medicine for the real world, today announced that the U.S. Food and Drug Administration (FDA) has approved Lamlique&trade… Source: Read More
-
Aquestive Therapeutics | FDA Acceptance of Libervant™ for Treatment of Seizure Clusters in Young Patients
NASDAQ: AQST The FDA has recently accepted the New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film, aiming to tackle the treatment of seizure clusters in children between the ages of two and five. This development provides hope for young patients and their families who have pbeen struggling with the challenges of managing seizure clusters.…